RxDoctor Payments Data

Sina Khasani, MD

Neurology · Brooklyn, NYNPI 1790704948

Payments from drug & device makers

$2,092in general payments, 2019–2025

Across 105 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$627
  • UCB, Inc.$182
  • Pfizer$163
  • Adamas Pharmaceuticals, Inc.$160
  • SK Life Science, Inc.$133
  • Acadia Pharmaceuticals Inc$89
  • plus $739 from 21 others

What the payments were for

  • Food & beverage$2,090100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,092 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$112,735
Medicare patients
416
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$100,297
IngrezzaValbenazine Tosylate13$99,893
Tetrabenazine13$96,301
QuliptaAtogepant61$62,399
RexultiBrexpiprazole37$55,699
UbrelvyUbrogepant34$50,451
AptiomEslicarbazepine Acetate15$47,713
Nurtec OdtRimegepant Sulfate16$35,322
Aimovig AutoinjectorErenumab-Aooe25$17,257
XadagoSafinamide Mesylate14$15,694
Emgality PenGalcanezumab-Gnlm18$14,287
Memantine Hcl282$7,133
HorizantGabapentin Enacarbil11$5,327
Lacosamide34$3,067
Venlafaxine Hcl ErVenlafaxine Hcl44$2,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$627$112,85095 claims
Neurocrine Biosciences, Inc.Ingrezza$44$99,89313 claims
Sunovion Pharmaceuticals Inc.Aptiom$39$47,71315 claims
PfizerNurtec Odt$163$35,32216 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$20$1,72915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →